Insights

Insight
September 2021

Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking

Insight
September 2021

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation

Insight
September 2021

The CBO Doesn’t Understand Investors

Insight
September 2021

H.R. 3 is the Wrong Policy for the Wrong Problem

Insight
September 2021

OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare

Insight
July 2021

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?

Insight
June 2021

Towards a New Understanding of Unmet Medical Need

Insight
June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Insight
May 2021

Would Waiving COVID-19 Vaccines Patents Save Lives?

Insight
April 2021

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Insight
April 2021

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Insight
April 2021

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Newsroom

The latest news and comment from OHE experts

Read Now

Subscribe To Our Newsletter

Our monthly Bulletin highlights our work alongside the latest from across health economics and health care.

News and Insights

Latest Research & Publications

Understanding the Full Value of Long-Acting Therapies: less is more?

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Analysing Global Immunisation Expenditure

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

The Importance of Diversity of Supply in Rare Diseases Markets

2023 OHE Annual Report to the Charity Commission

Employer Costs from Respiratory Infections

All Publications

Filter results by

Around the World in HTAs: Canada – Autonomous yet Collaborative

Driving Green Change: Lessons from the 2024 Innovation Policy Prize

Filter results by

Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation

The CBO Doesn’t Understand Investors

H.R. 3 is the Wrong Policy for the Wrong Problem

OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?

Towards a New Understanding of Unmet Medical Need

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Would Waiving COVID-19 Vaccines Patents Save Lives?

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Newsroom

Subscribe To Our Newsletter

Share on Mastodon